Clinical Trial

Clinical Outcome of Palliative Surgery After Translational Therapy for Metastatic Gastric Cancer Versus Maintenance Chemotherapy for Metastatic Gastric Cancer

Not Yet Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated April 1, 2022 (before its estimated March 1, 2024 completion). Its status may not reflect the trial's current state.
Summary
This single-center, prospective study was conducted to investigate the efficacy and safety of palliative surgery after translational therapy in the treatment of metastatic gastric cancer. The primary endpoint was 2-year overall survival (OS) rate. Secondary endpoints were median OS, progression-free survival (PFS), 1-year OS, adverse events (AE), severe AE, the quality of life (QOL) and treatment cost.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2022-01-29; most recent amendment 2022-03-30.
Trial Details
NCT Number NCT05230771
Lead Sponsor Fujian Medical University
Conditions Metastatic Gastric Cancer, Surgery, Chemotherapy
Enrollment 120 participants
Start Date 2022-04-01
Primary Completion 2024-03-01 (estimated)
Study Completion 2027-03-01 (estimated)
Updated on ClinicalTrials.gov 2022-04-01